Alex Hammond

Could you comment on when we should start seeing results from your Skyrizi and Rinvoq combination trials

how do you kind of expect to maintain this leadership position when other manufacturers launch biosimilars in the second half of the year?

Could we see PK comparability versus randomized Phase III trials to be feasible? And how could these dynamics possibly modulate your long-term guidance of greater than $4 billion in sales by 2030?

Are you thinking a 50-50 split in, let's say, the atopic dermatitis market? Or how are you kind of thinking about that shaking out?

what is Amgen's stance on looking overseas for clinical-stage assets? And I guess more broadly, what is your appetite for M&A now post the Horizon acquisition?

what's the potential in other telophase

Can you walk us through how to think about the cadence of sales growth this year

Can you help us think through how you'd approach a subgroup analysis, particularly for patients where the risk

Can you imply the key assets you expect to drive revenue looking at the back end of the decade

How should we think about margins in the near term and the long term? Is there room for continued margin expansion

How should we think about the potential of the 340B channel mix on HIV pricing for '25

Can you walk us through the investments you guys are making on prescriber and patient education

how important could this result be those ongoing commercial discussions

On Milvexian, can you talk a little bit about confidence in this asset? What do you think you'll need to show to be competitive

Why now, why the orthopedic separation? It's been a hallmark of Johnson & Johnson to be a good steward

can you walk us through J&J's launch strategy? Are there sales force training, supply chain, patient access

For CAPLYTA, how should we be thinking about the cadence of sales growth to the forecasted sales of $5 billion?

can you walk us your strategy to activate these patients -- and when do you kind of see this playing out

how should we think about the potential for lower doses of oloralintide and lower dose combos of tirzepatide

Can you walk us through the importance of the upcoming ATTAIN-MAINTAIN trial to orforglipron's commercial opportunity

Can you update us as to where we are from that events point of view and remind us of what a successful trial looks like?

how does Lilly envision this relationship evolving? And a follow-up, can you help frame the opportunity associated with Zepbound vials?

how should we model the IP runway for KEYTRUDA? And how should we think about the timing

What's the bar to deem the trial a success? And I guess given the competitive nature of this indication

what combinations and indications could we expect? And when could we receive updates

How important do you see this wording update to an impact to US sales

can you just walk us through your commercialization strategy

When could we expect an update, and what are expectations for the launch if positive? What does vaccine contracting look like and what channels will be the key target

Can you elaborate more on the reason for the delay to the initiation of the pivotal trial for the adult 25-valent pneumococcal program

how should we consider the applicability of this program to the remainder of your portfolio?

with new competitors on the market and on the way, can you walk us through how we should think about the near-term commercial dynamics?

Can you share a little bit more on your clinical strategy to exhibit that development of your next-gen I&I assets

any update on when we could receive this data beyond first half? Should we expect to get an adjuvant interim update

could you share your confidence in demonstrating a static benefit against KEYTRUDA

one of the lesser talked about programs is Regeneron's poze-cemdi readout in gMG

how do you prioritize which indications to go after? And how should we think about the timing of launches